EBITDA: Income before interest, taxes, depreciation and amortization.
Roivant Sciences Ltd. (ROIV) had EBITDA of $415.88M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$2.52M |
|
$302.99M |
|
$0.32M |
|
$2.20M |
|
$-412.72M |
|
$415.24M |
|
$38.86M |
|
$454.10M |
|
$480.02M |
|
$355.74M |
|
$355.74M |
|
$355.74M |
|
$427.55M |
|
$415.24M |
|
|
EBITDA |
$415.88M |
693.87M |
|
693.87M |
|
$0.45 |
|
$0.34 |
|
| Balance Sheet Financials | |
$5.17B |
|
$11.99M |
|
$541.30M |
|
$5.71B |
|
$281.24M |
|
-- |
|
$135.03M |
|
$416.27M |
|
$5.29B |
|
$5.29B |
|
$5.29B |
|
720.35M |
|
| Cash Flow Statement Financials | |
$-750.35M |
|
$-682.33M |
|
$134.24M |
|
$2.73B |
|
$1.43B |
|
$-1.29B |
|
$346.17M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
18.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
87.30% |
|
16477.78% |
|
16477.78% |
|
-- |
|
18019.72% |
|
12023.57% |
|
$-758.56M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.00 |
|
0.03M |
|
6.72% |
|
6.72% |
|
6.23% |
|
6.72% |
|
$7.35 |
|
$-1.09 |
|
$-1.08 |
|